

a second sample sent for LS analysis. The cause of the original effusion was agreed by two independent consultants after a minimum 12 month follow-up period.

Results 395 patients with undiagnosed effusions were seen, of which 124(31%) were found to be lymphocytic on initial examination. 35(28.2%) patients were excluded due to confirmed (non-haematological) malignancy (11 initial cytology, 24 biopsy). A further 46(37.1%) patients were excluded with confirmed benign diagnoses including inflammatory pleuritis, heart failure and pleural infection. 39/43 (90.7%) patients therefore had samples sent for LS analysis.

7/43 (16.3%) patients' effusions were diagnosed at 12 months as primarily due to lymphoma, with 5 having a previous diagnosis of such. Their characteristics are described in the table below.

LS analysis was diagnostic in 4 and negative in 35 cases. There were no false positive results. Therefore, based on these data, for determining whether there is haematological malignancy in lymphocytic pleural fluid, LS analysis has a sensitivity of 57.1%, a specificity of 100%, and a positive and negative predictive value of 100% and 91.4% respectively.

Conclusions LS analysis appears useful in a selected subgroup of patients presenting with undiagnosed effusions. It should only be considered in those patients with a lymphocytic effusion which shows negative initial cytology and/or no firm diagnosis established on pleural biopsy, or those with a past medical history of a lymphoma. A negative LS result does not exclude the possibility of a haematological cause for the effusion.

Abstract P209 Table 1. Investigations and characteristics of patients with confirmed lymphoma who underwent pleural fluid lymphocyte subsets analysis.

Patient	Disease	Comorbidities	History of lymphoma	LS positive	Tissue obtained	Tissue diagnostic?
1	DLBCL	Nil	No	No	Marrow	Yes
2	DLBCL	AF	Yes	Yes	Marrow	No
3	DLBCL	CCF, AF	Yes	No	Node	Yes
4	Low grade NHL	Nil	Yes	Yes	Too frail	
5	Low grade NHL	Nil	Yes	No	Too frail	
6	CLL	Nil	Yes	Yes	No	
7	CLL	T2DM, AF	No	Yes	Thoracoscopy	Yes

DLBCL=Diffuse large B-cell Lymphoma, NHL=Non-Hodgkin's Lymphoma, CLL=Chronic Lymphocytic Leukaemia

P210 DEFINING THE MINIMAL IMPORTANT DIFFERENCE FOR THE VISUAL ANALOGUE SCALE FOR DYSPNOEA IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS

¹EK Mishra, ¹J Corcoran, ¹R Hallifax, ¹J Stradling, ²N Maskell, ¹N Rahman; ¹University of Oxford, Oxford, UK; ²University of Bristol, Bristol, UK

10.1136/thoraxjnl-2013-204457.362

Background Malignant pleural effusions (MPEs) cause disabling dyspnoea in over 1 million people worldwide per year. Currently recruiting and recently reported randomised controlled trials (RCTs) use the visual analogue scale for dyspnoea (VASD) to assess mean daily breathlessness in patients with MPEs (ISRCTN12852177, ISRCTN4784593, ISRCTN73255764) in order to provide evidence for the optimal method of symptom palliation. The VASD consists of a 100 mm line which subjects mark at a point representing their dyspnoea intensity.

Determination of the minimal important difference (MID) for the VASD in patients with MPEs is essential to interpret the results of these trials.

Methods Patients with a confirmed or suspected MPE undergoing a pleural procedure recorded their baseline VASD prior to the procedure and, 24 hours later, their post-procedure VASD and assessed their dyspnoea on a 7 point Likert scale. Age, gender, diagnosis, procedure performed and volume of fluid drained were also recorded.

Results A total of 114/123 (93%) questionnaires were returned. Mean age of respondents was 70 years and 56% were female. Commonest malignancies were breast (41%), mesothelioma (26%) and non-small cell lung cancer (18%). Procedures included: therapeutic aspiration (35%), medical thoracoscopy (27%), chest drain insertion (11%), diagnostic tap (11%) and indwelling pleural catheter insertion (8.8%). The mean decrease in VASD in patients reporting a 'small but just worthwhile decrease' in their dyspnoea (i.e. equivalent to the MID) was 19mm (95% CI 14–24 mm). The volume of fluid required to drain to produce a change in VASD of 19mm was 760ml. Mean decrease in VASD for the different procedures were: chest drain 41mm; IPC insertion and drainage 41mm; therapeutic aspiration 31mm; diagnostic aspiration 19mm; and LAT 24mm.

Conclusion The MID for the VASD in patients with a MPE undergoing a pleural procedure is 19mm (95% CI 14–24mm). This value should be used when interpreting the results of RCTs in patients with MPEs using the VASD as an outcome measure and to calculate the sample size for future RCTs.

P211 DOMICILIARY CARE OF PATIENTS WITH PRIMARY AND SECONDARY PNEUMOTHORACES: OUR EXPERIENCE IN AYRSHIRE, PATIENT SATISFACTION AND HEALTH ECONOMIC ANALYSIS

¹A Guhan, ¹S Learmonth, ²O Moseley, ¹D Sword, ¹F Kelly; ¹University Hospital Ayr, NHS Ayrshire and Arran, Ayr, United Kingdom; ²NHS Ayrshire and Arran, Ayr, United Kingdom

10.1136/thoraxjnl-2013-204457.363

Background Domiciliary care (DC) of Spontaneous Pneumothoraces (SP) with an ambulatory Heimlich Valve (HV) attached to the Intercostal Chest Drain (ICD) has potential for care-closer-to-home, avoiding hospitalisation and saving healthcare resources. Wider acceptance of this practice requires demonstration of tangible benefits in terms of patient safety, patient satisfaction and cost savings.

Method In the last year (since July 2012), we established a consultant-led DC service for SP at the University Hospital Ayr, Ayrshire. All primary (PSP) or secondary (SSP) SP admitted through The Emergency Department (ED) were assessed within 48 hours for potential DC with informed consent, based on presence of Persistent Air Leak and predetermined criteria ensuring patient safety (Table:1). All DC patients had 72 hourly consultant ward reviews (CWR) with chest Xray or sooner should patients identify HV non-movement with coughing. ICD was removed when SP resolved. SP patients on DC were readmitted if concerns were identified. Patient satisfaction was assessed formally (Table 6).

Health economics: Costs were calculated from an NHS perspective by examining resource use associated with DC for SP. This figure was then compared against the potential cost-avoidance in terms of respiratory medicine bed days saved. Costs were taken from published ISD reference costs when available and local